ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Since imatinib (Glivec or Gleevec) has been used to target the BCR-ABL fusion protein, chronic myeloid leukemia (CML) has become a manageable chronic disease with long-term survival.